Impact of the Pharma Economic Act on Diffusion of Innovation and Reduction of Costs in the Hungarian Prescription Drug Market (2007–2010) Rok Hren, PhD,

Slides:

Advertisements

Similar presentations

Performance Assessment of the Juaboso District Office of the National Health Insurance Authority Paul Effah, MBA, Kingsley Opoku Appiah, PhD, FCCA, Patience.

Advertisements

Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia Juan-Carlos Castro, MD,

Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis Klára Kruntorádová, MSc, Jiří Klimeš,

Examining the Value of Menopausal Symptom Relief Among US Women

Value and Service Quality Assessment of the National Health Insurance Scheme in Ghana: Evidence from Ashiedu Keteke District Eric Nsiah-Boateng, MSc,

Investigating the Economic Impacts of New Public Pharmaceutical Policies in Greece: Focusing on Price Reductions and Cost-Sharing Rates Siskou Ch. Olga,

Value in Health Regional Issues

Eric Nsiah-Boateng, MPH, Moses Aikins, PhD

Value and Service Quality Assessment of the National Health Insurance Scheme in Ghana: Evidence from Ashiedu Keteke District Eric Nsiah-Boateng, MSc,

An Audit of Diabetes-Dependent Quality of Life (ADDQOL) in Older Patients with Diabetes Mellitus Type 2 in Slovenia Eva Turk, MA, MBA, Valentina Prevolnik.

The Development of the Romanian Scorecard HTA System

Using Dynamic Transmission Modeling to Determine Vaccination Coverage Rate Based on 5-Year Economic Burden of Infectious Disease: An Example of Pneumococcal.

Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.

Systematic Review of Economic Evaluation Literature in Ghana: Is Health Technology Assessment the Future? Emmanuel Ankrah Odame, MBCHB, MPH Value in.

The Cost-Effectiveness Analysis of a Quadrivalent Human Papillomavirus Vaccine (6/11/16/18) for Females in Japan Kaoru Yamabe, MSc, Puneet K. Singhal,

Prevalence, Awareness, Treatment, and Burden of Major Depressive Disorder: Estimates from the National Health and Wellness Survey in Brazil Ronaldo K.

Value in Health Regional Issues

Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs)

An Overview of the Orphan Medicines Market in Turkey

The Process of Privatization of Health Care Provision in Poland

Boxiong Tang, MD, PhD, Eran Harary, MD, Ricky Kurzman, MSc, Joaquín F

Ernest Attuquaye Quaye, BPharm, MPH, Edward O

The Living with Medicines Questionnaire: Translation and Cultural Adaptation into the Arabic Context Amani Zidan, BScPharm, Ahmed Awaisu, PhD, Sanah.

Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis Klára Kruntorádová, MSc, Jiří Klimeš,

Cost-Effectiveness of Sertindole among Atypical Antipsychotics in the Treatment of Schizophrenia in South Korea Bo-Ra-Mi Kim, MPH, Tae-Jin Lee, PhD,

Radiology Services Costs and Utilization Patterns Estimates in Southeastern Europe—A Retrospective Analysis from Serbia Mihajlo Jakovljević, MD, PhD,

Capacity Building for HTA Implementation in Middle-Income Countries: The Case of Hungary Zoltán Kaló, MSc, MD, PhD, József Bodrogi, MSc, Imre Boncz,

Rutger Daems, PhD, Edith Maes, DBA, Christoph Glaetzer, Dipl, Kfm

Cost-Benefit Analysis and Assessment of Quality of Care in patients with Hemophilia undergoing treatment at National Rural Health Mission in Maharashtra,

Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore Vivianne Shih, PharmD, BCOP, BCPS, Alexandre Chan, PharmD,

What Is Important During the Selection of Traditional Chinese Medicine (TCM) in a Health Care Reimbursement or Insurance System?” Critical Issues of Assessment.

Jinhyun Kim, PhD, Eunhee Lee, PhD, Sungjae Kim, PhD, Tae Jin Lee, PhD

Burden of Disease and Economic Impact of Dengue and Severe Dengue in Colombia, 2011 Carlos Castañeda-Orjuela, MD, MSc, Hernando Díaz, PhD, Nelson Alvis-Guzman,

The Potential Effects of Implementing the 2013 ACC/AHA Cholesterol Guidelines on the Use of Statins in a Large Health Maintenance Organization in Israel

Cost-Effectiveness Analysis of Atorvastatin versus Rosuvastatin in Primary and Secondary Cardiovascular Prevention Populations in Brazil and Columbia

Bernadette A. Tumanan-Mendoza, MD, MScE, MHE, Victor L. Mendoza, MD

Patient-Reported Outcomes in Latin America: Implementation in Research and Role in Emerging HTA Systems Randall Winnette, MSc, Victor Zárate, MD, MSc,

Omneya Mohamed, PhD, David H. Kreling, PhD

Onur Baser, MS, PhD, Akif Altinbas, MD, Erdem Baser, MS, M

Value in Health Regional Issues

The Economic Impact of Cigarette Smoking on the Poor in Jordan

Burden of Disease Studies in the Asia-Pacific Region: Are There Enough being Performed to Provide Information for Evidence-Based Health Policy? Fei-Li.

A Framework for Applying Health Technology Assessment in Cyprus: Thoughts, Success Stories, and Recommendations Panagiotis Petrou, MBA, PhD, PhDc, Michalis.

Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.

Children Hospitalized for Varicella: Complications and Cost Burden

Transforming Public Servants’ Health Care Organization in Greece through the Implementation of an Electronic Referral Project Kyriakos Souliotis, PhD,

Economic Burden of Individual Suffering from Atrial Fibrillation–Related Stroke in China Shanlian Hu, MSc, Lin Zhan, MSc, Bao Liu, MD, PhD, Yue Gao, MD,

Generalized Cost-Effectiveness Analysis of Pharmaceutical Interventions for Primary Prevention of Cardiovascular Disease in Thailand Panrasri Khonputsa,

The Methodological Challenges for the Estimation of Quality of Life in Children for Use in Economic Evaluation in Low-Income Countries Travor Mabugu,

Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes Maxwell O. Adibe,

Drug Utilization Reviews by Community Pharmacists in Japan: Identification of Potential Safety Concerns through the Brown Bag Program Manabu Akazawa,

Results of the Inclusion of New Medications in the Obligatory Health System Plan in Colombia, 2012–2013 Jorge Enrique Machado-Alba, PhD, Daniel Torres,

Reconciling Cancer Care Costs Reported by Different Government Agencies in Taiwan: Why Costing Approach Matters? Chun-Ru Chien, MD, PhD, Ya-Chen Tina.

Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia Juan-Carlos Castro, MD,

Economic Evaluation of Pravastatin for Primary Prevention of Coronary Artery Disease Based on Risk Prediction from JALS-ECC in Japan Yoshie Onishi, MS,

Use of the EQ-5D Instrument and Value Scale in Comparing Health States of Patients in Four Health Care Programs among Health Care Providers Valentina.

Pei Wang, PhD, Nan Luo, PhD, E.S. Tai, PhD, Julian Thumboo, PhD

Value in Health Regional Issues

Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea Ji Haeng Heo, MS, Karen L.

Dossier System as a Practical Tool for Compiling Reimbursement Lists

Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not.

Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico

Performance Assessment of the Juaboso District Office of the National Health Insurance Authority Paul Effah, MBA, Kingsley Opoku Appiah, PhD, FCCA, Patience.

Social Cost of Substance Abuse in Russia

Economic Evaluation of Four Drug Administration Systems in Intensive Care Units in Colombia Diego Rosselli, MD, MSc, Juan David Rueda, MD, María Daniela.

Clinical Burden of Invasive Pneumococcal Disease in Selected Developing Countries Namaitijiang Maimaiti, PhD, Zafar Ahmed, PhD, Zaleha Md Isa, PhD, Hasanain.

Victoria I. Ignatyeva, MPH, Johan L

Drug Policy in Hungary Value in Health Regional Issues

Cost-Effectiveness of the Combined Use of Warfarin and Low-Dose Aspirin versus Warfarin Alone in Egyptian Patients with Aortic Valve Replacements: A Markov.

Abdol Majid Cheraghali, PhD, Peyman Eshghi, MD

Presentation transcript:

Impact of the Pharma Economic Act on Diffusion of Innovation and Reduction of Costs in the Hungarian Prescription Drug Market (2007–2010) Rok Hren, PhD, MSc, IHP (HE) Value in Health Regional Issues Volume 2, Issue 2, Pages 290-299 (September 2013) DOI: 10.1016/j.vhri.2013.06.013 Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 1 Public prescription drug expenditure in Hungary between 2003 and 2010 [2], shown in million HUF. Two counterfactual curves are displayed: one for 6% annual growth rate and one for the CAGR of 16.9% for the period 2003 to 2006. CAGR, compound annual growth rate; GR, growth rate; HUF, Hungarian forint. Value in Health Regional Issues 2013 2, 290-299DOI: (10.1016/j.vhri.2013.06.013) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 2 Public prescription drug expenditure along with out-of-pocket co-payment and “co-payment” covered by the social welfare for disadvantaged population in Hungary between 2003 and 2010 [2], shown in million HUF. HUF, Hungarian forint. Value in Health Regional Issues 2013 2, 290-299DOI: (10.1016/j.vhri.2013.06.013) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 3 Public expenditure, including 12% rebate, for statins (ATC4 group C10AA) between 2006 and 2010 [2], shown in million HUF. HUF, Hungarian forint. Value in Health Regional Issues 2013 2, 290-299DOI: (10.1016/j.vhri.2013.06.013) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 4 Public expenditure along with out-of-pocket and social welfare co-payments for atorvastatins (ATC5 group C10AA05) between 2006 and 2010 [2], shown in million HUF. A counterfactual curve based on the trend in the period 2004 to 2006 is displayed. HUF, Hungarian forint. Value in Health Regional Issues 2013 2, 290-299DOI: (10.1016/j.vhri.2013.06.013) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 5 Number of units (in per-30-tablets equivalents) and total milligrams of atorvastatin dispensed in Hungarian pharmacies between 2003 and 2010 [2]. Value in Health Regional Issues 2013 2, 290-299DOI: (10.1016/j.vhri.2013.06.013) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 6 Prices (in HUF) of atorvastatin 40 mg (30 tablets) for an off-patent originator and various generic bioequivalent alternatives between January 2007 and January 2011 [2]. HUF, Hungarian forint. Value in Health Regional Issues 2013 2, 290-299DOI: (10.1016/j.vhri.2013.06.013) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 7 Total milligrams of long-acting atypical antipsychotics dispensed in the Hungarian prescription drug market between 2005 and 2010 [2]. Value in Health Regional Issues 2013 2, 290-299DOI: (10.1016/j.vhri.2013.06.013) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 8 Number of units of bortezomib dispensed in the Hungarian prescription drug market between 2004 and 2010 [2]. Value in Health Regional Issues 2013 2, 290-299DOI: (10.1016/j.vhri.2013.06.013) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions